Archive - June 2021
Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients
Eli Lilly demonstrates Verzenio win in high-risk breast cancer subset at ASCO
Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
Positive results for AZ, Merck & Co’s Lynparza in early breast cancer presented at ASCO
Tickets now on sale for INTCR 2021
GSK’s PD-1 inhibitor Jemperli approved in the UK
Amgen’s KRAS inhibitor Lumakras scores positive overall survival data
Iksuda Therapeutics raises $47m to progress ADC pipeline